» Non-Financial

Company Directors
Company Advisors
New & Press Releases
Directors Share Dealings
Major Shareholders
Company Subsidiary Calendar of Future Events
Company Name Change
Company Status Change

» Analyst Spreadsheet

Quick View(PDF)
Trader(PDF)
Dossier(PDF)
Download Analyst Template
Analyst Spreadsheet
Download Master Template
Annual Master Spreadsheet
Quarterly Master Spreadsheet
Annual & Quaterly Master Spreadsheet
Valuation Model Template
Valuation Model Spreadsheet
Business Risk(PDF)
Credit Metrics(PDF)
Annual Reports

For all products and/or service inquiries or to learn more about how WVB customer service solutions can reduce your service costs while increasing customer satisfaction, email us at .

IN8BIO

WVB Number : USA000070728 Country : United States of America
SIC categorization : BIOLOGICAL PDS,EX DIAGNSTICS (2836) ISIN : US45674E1091
FT categorization : HEALTH CARE (431)  
Company status: ACTIVE  

» Corporation Profile :

Profile in brief:
The Company is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue.
Phone : 1 Fax :
Chairman: : N/A Auditor : COHNREZNICK LLP
CEO/Managing Director : N/A

» Company Facts

Net Profit Margin (%) N/A  
Operating Margin (%) N/A  
Return on Assets (%) -77.65  
Return on Equity (%) 66.28  
Employees N/A  

» Company Financials

  Annual (2020)
Income Statement
('000 USD )
Sales/Total Revenue 0  
EBITDA -8,457  
EBIT -8,557  
Net Income -8,557  
Balance Sheet
( '000 USD)
Total Current Assets 18,144  
Total Assets 20,910  
Current Liabilities 2,572  
Total Liabilities & Debt 2,589  
Total Equity -16,579  
Cash & Flow
( '000 USD)
Net Income/Staring Line -8,557  
Cash from Operating -7,133  
Cash from Investing 0  
Cash from Financing 24,517  
Cash & Equivalent Yr End 17,994